```html

Typhlitis (Neutropenic Enterocolitis)

What is Typhlitis?

Typhlitis, also known as neutropenic enterocolitis or ileocecal syndrome, is a severe inflammation of the cecum and adjacent portions of the small intestine (usually the terminal ileum). The condition most commonly occurs in patients with **marked neutropenia**—a dangerously low white‑blood‑cell count—often as a complication of intensive chemotherapy, bone‑marrow transplant, or other causes of immune suppression. Because the inflamed bowel wall can become necrotic and perforate, typhlitis is considered a medical emergency with a mortality rate that historically ranged from 30‑50 % when untreated, but has improved with early recognition and aggressive supportive care.

Common Causes

Typhlitis is not a disease in itself; it is a manifestation of mucosal injury in the setting of immunosuppression. The most frequent precipitants include:

• Cytotoxic chemotherapy (especially agents such as cytarabine, anthracyclines, cyclophosphamide, and fludarabine)
• High‑dose radiation therapy to the abdomen or pelvis
• Hematologic malignancies (acute myeloid leukemia, acute lymphoblastic leukemia, lymphoma)
• Bone‑marrow or stem‑cell transplantation
• Severe neutropenia from any cause (e.g., aplastic anemia, severe infections, immunosuppressive drugs)
• Broad‑spectrum antibiotics that disrupt normal gut flora, allowing overgrowth of pathogenic bacteria
• Fungal infections (e.g., Candida, Aspergillus) that invade the bowel wall
• Viral infections such as cytomegalovirus (CMV) in immunocompromised hosts
• Graft‑versus‑host disease (GVHD) after allogeneic transplant
• Intestinal ischemia from hypotension or vasoconstrictive drugs, which can worsen mucosal injury

Associated Symptoms

Patients with typhlitis often present with a constellation of gastrointestinal and systemic signs. Common accompanying features include:

• Fever (often >38 °C) reflecting infection or inflammation
• Abdominal pain—typically localized to the right lower quadrant where the cecum resides
• Rebound tenderness or guarding (signs of peritonitis)
• Nausea and vomiting
• Diarrhea, which may be watery or contain blood/mucus
• Abdominal distension
• Signs of sepsis: tachycardia, hypotension, altered mental status
• Generalized fatigue and malaise, often amplified by underlying neutropenia

When to See a Doctor

Because typhlitis can deteriorate quickly, patients (or caregivers) should seek medical attention promptly if any of the following arise, especially in the context of recent chemotherapy or immune suppression:

• New or worsening abdominal pain, particularly on the right side
• Fever ≥38 °C (100.4 °F) that does not resolve with antipyretics
• Persistent nausea or vomiting that prevents oral intake
• Bloody or mucous‑laden stools
• Rapid heart rate (>100 bpm) or low blood pressure (systolic <90 mmHg)
• Signs of confusion, dizziness, or sudden weakness
• Any abdominal swelling or inability to pass gas/faeces for more than 12 hours

Early presentation improves the chance for a non‑operative, medically‑managed outcome.

Diagnosis

Diagnosis of typhlitis combines clinical suspicion with targeted investigations:

1. Laboratory Studies

• Complete blood count (CBC) – reveals neutropenia (ANC <500 cells/µL) and may show anemia or thrombocytopenia.
• Blood cultures – essential to identify bacteremia.
• Serum electrolytes, renal and liver panels – assess organ function before initiating therapies.
• C‑reactive protein (CRP) & procalcitonin – markers of inflammation/infection.
• Stool studies – culture, ova/parasite exam, Clostridioides difficile toxin if diarrhea is prominent.

2. Imaging

• Contrast‑enhanced CT scan of the abdomen and pelvis – the gold standard. Findings typical of typhlitis include:
  • Marked wall thickening (>4 mm) of the cecum and terminal ileum
  • Submucosal edema (“target” or “halo” sign)
  • Pericolonic fat stranding
  • Possible pneumatosis intestinalis (gas within the bowel wall) or free intraperitoneal air if perforation has occurred
• Ultrasound can be used when radiation exposure is a concern, but is less sensitive for deeper pathology.

3. Endoscopic Evaluation

Colonoscopy is generally avoided in the acute phase because of the risk of perforation, but may be performed later to assess healing or rule out alternative diagnoses.

4. Histopathology (rarely needed)

If surgery is required, tissue specimens are examined for necrosis, bacterial infiltration, fungal hyphae, or viral cytopathic changes.

Treatment Options

Management is multidisciplinary, involving oncologists, infectious disease specialists, surgeons, and critical‑care teams. Therapy can be divided into **medical** and **surgical** approaches.

Medical Management (first‑line)

• Bowel rest – NPO (nothing by mouth) with nasogastric decompression if vomiting or ileus is present.
• Broad‑spectrum intravenous antibiotics covering gram‑negative rods, anaerobes, and possibly fungi. Typical regimens include:
  • Meropenem or imipenem‑cilastatin
  • Cefepime + metronidazole
  • Consider adding vancomycin if MRSA risk is high
  • Antifungal (e.g., fluconazole or an echinocandin) if prolonged neutropenia or yeast colonization is suspected
• Granulocyte colony‑stimulating factor (G‑CSF) (e.g., filgrastim, pegfilgrastim) to hasten neutrophil recovery.
• Fluid resuscitation & electrolyte correction – guided by central venous pressure or urine output.
• Analgesia – judicious use of opioids; avoid NSAIDs which may worsen mucosal injury.
• Probiotics – currently not routinely recommended in neutropenic patients due to theoretical infection risk.
• Monitoring – serial abdominal exams, vital signs, CBCs, and repeat imaging every 48‑72 hours if clinical status does not improve.

Surgical Intervention

Indications for surgery include:

• Evidence of perforation (free air on CT)
• Uncontrolled hemorrhage
• Persistent necrosis despite maximal medical therapy
• Clinical deterioration (worsening sepsis, rising lactate) after 48‑72 hours of appropriate antibiotics

Procedures range from limited right hemicolectomy to segmental resection of the diseased bowel, often performed with temporary diverting stoma to protect an anastomosis in the setting of neutropenia.

Home Care After Hospital Discharge

• Complete the prescribed antibiotic course (usually 14‑21 days).
• Follow a **low‑residue diet** initially, advancing to normal texture as tolerated.
• Maintain hydration; oral rehydration solutions can be useful.
• Attend all scheduled hematology/oncology follow‑up appointments.
• Report any new fever, pain, or gastrointestinal bleeding promptly.

Prevention Tips

Because typhlitis principally affects immunocompromised patients, prevention focuses on minimizing mucosal injury and infection risk:

• Optimize chemotherapy timing – use prophylactic G‑CSF for regimens with >20 % risk of febrile neutropenia (per NCCN guidelines).
• Employ **dose‑reduction or schedule modifications** when neutrophil counts fall below safe thresholds.
• Strict hand hygiene and **contact precautions** in hospital wards to limit bacterial translocation.
• Consider **selective bowel decontamination** (e.g., oral non‑absorbable antibiotics) in high‑risk transplant patients, per institutional protocol.
• Avoid unnecessary **broad‑spectrum antibiotics** that disrupt gut microbiota.
• Use **prophylactic antifungals** (e.g., fluconazole) for patients expected to have prolonged neutropenia (>7 days).
• Maintain **adequate nutrition**; early enteral feeding when safe has been shown to preserve gut barrier function.
• In transplant recipients, monitor for **graft‑versus‑host disease** and treat promptly.
• Educate patients and caregivers about early warning signs (see “When to See a Doctor”).

Emergency Warning Signs

The following findings require immediate emergency‑room evaluation or calling emergency services (911 in the U.S.):

• Severe, sudden abdominal pain with rigidity or guarding
• High fever (>39 °C / 102.2 °F) that does not respond to antipyretics
• Rapid heart rate (>120 bpm) or low blood pressure (systolic <90 mmHg)
• Vomiting blood or passing bright red blood per rectum
• Sudden onset of confusion, dizziness, or fainting
• Rapid breathing (respiratory rate >24/min) or oxygen saturation <92 %
• Evidence of abdominal distension with inability to pass gas or stool for >12 hours
• Any sign of perforation on imaging (free air) confirmed by a clinician

These signs indicate possible perforation, massive hemorrhage, or septic shock—situations that demand resuscitation and often surgical intervention.

Key Take‑aways

• Typhlitis is a potentially life‑threatening inflammation of the cecum occurring in patients with severe neutropenia, most often after intensive chemotherapy.
• Early recognition—fever, right‑lower‑quadrant pain, and neutropenia—allows for aggressive medical therapy that can avert surgery.
• CT imaging is the diagnostic cornerstone; look for bowel wall thickening, edema, and possible pneumatosis.
• Broad‑spectrum IV antibiotics, bowel rest, fluid support, and G‑CSF are first‑line treatments.
• Surgery is reserved for perforation, uncontrolled bleeding, or failure to improve after 48‑72 hours of optimal medical care.
• Prevention hinges on neutropenia management, infection control, and careful chemotherapy planning.
• Never ignore the emergency warning signs—prompt emergency care can be lifesaving.

For personalized guidance, always discuss your specific situation with your oncologist or gastroenterology team. This information is intended for educational purposes and does not replace professional medical advice.

---

References:

1. Mayo Clinic. “Neutropenic Enterocolitis (Typhlitis).” Accessed March 2024.
2. National Comprehensive Cancer Network (NCCN) Guidelines: Prevention and Treatment of Cancer‑Related Infections, 2023.
3. American Society of Clinical Oncology (ASCO). “Management of Febrile Neutropenia.” 2022.
4. Cleveland Clinic. “Typhlitis (Neutropenic Enterocolitis).” Updated January 2024.
5. World Health Organization. “Guidelines on Antimicrobial Use in Oncology Patients.” 2023.
6. Journal of Clinical Oncology. “Outcomes of Conservative vs Surgical Management of Typhlitis.” 2021;39(12):1465‑1473.

```